Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient

Publisher： John Wiley & Sons Inc

E-ISSN： 1758-5872|10|1|appy.12300-appy.12300

ISSN： 1758-5864

Source： ASIA-PACIFIC PSYCHIATRY (ELECTRONIC), Vol.10, Iss.1, 2018-03, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

By Gopal S. Gassmann-Mayer C. Palumbo J. Samtani M.N. Shiwach R. Alphs L.

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 377-387

Informa Healthcare

Access to resources Recommend Favorite

Validation of an economic model of paliperidone palmitate for chronic schizophrenia

By Einarson Thomas R. Hemels Michiel E. H.

Journal of Medical Economics, Vol. 16, Iss. 11, 2013-11 ,pp. : 1267-1274

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia

Reviews on Recent Clinical Trials, Vol. 7, Iss. 1, 2012-02 ,pp. : 2-9

Bentham Science Publishers

Access to resources Recommend Favorite

Relationship of serum testosterone levels with cognitive function in chronic antipsychotic‐treated male patients with schizophrenia

ASIA-PACIFIC PSYCHIATRY (ELECTRONIC), Vol. 7, Iss. 3, 2015-09 ,pp. : 323-329

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

By Kozma Chris M. Slaton Terra Dirani Riad Fastenau John Gopal Srihari Hough David

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1603-1611

Informa Healthcare

Access to resources Recommend Favorite